IOVANCE BIOTHERAPEUTICS, INC. Net Income Loss

• IOVANCE BIOTHERAPEUTICS, INC. showed a decrease of -5.1% in Net Income Loss from 2024 to 2025.
• This data is from IOVANCE BIOTHERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 18 years of available data (2008 to 2025), IOVANCE BIOTHERAPEUTICS, INC.'s Net Income Loss has declined by 665,779.8%.
• Historical annual values: Fiscal year 2025: -$390.98 million | Fiscal year 2024: -$372.18 million | Fiscal year 2023: -$444.04 million | Fiscal year 2022: -$395.89 million | Fiscal year 2021: -$342.25 million | Fiscal year 2020: -$259.58 million | Fiscal year 2019: -$197.56 million | Fiscal year 2018: -$123.58 million | Fiscal year 2017: -$92.06 million | Fiscal year 2016: -$52.89 million | Fiscal year 2015: -$27.66 million | Fiscal year 2014: -$12.04 million | Fiscal year 2013: -$25.38 million | Fiscal year 2012: -$3.31 million | Fiscal year 2011: -$25.69 million | Fiscal year 2010: -$1.61 million | Fiscal year 2009: -$15.8 thousand | Fiscal year 2008: -$58.7 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026